Supplemental Figure S1. Hierarchical clustering of the six RHC-specific subgroups.



Supplemental Figure S2. Hierarchical clustering of the five crack-entry-specific subgroups.



Supplemental Figure 3. qRT-PCR verification of a subset of differential tags.

Reactions were done on tissue from a biological repeat. For each tag, qRT-PCR results are shown (bars) with the cDNA-AFLP profile on the right. Expression levels are given as fold change, relative to the non-inoculated controls for each series. Time points are described in Figure 1 and 2. A, Chitinase (043BT43M22-372.0). B, L-asparaginase (048BT32M12-658.6). C, GA20-oxidase (041BT42M22-281.9). D, MAP kinase NTF6 (020BT23M14-343.0). E, Subtilisin-like protease (029BT31M41-395.6). F, Response regulator protein (002BT11M22-259.3). G, Putative low-affinity nitrate transporter (022BT24M13-265.0). H, Yippee-like protein (011BT14M33-415.0). I, GDSL motif lipase/hydrolase-like protein (024BT24M42-288.2). J, MtN21 nodulin (042BT42M42-325.2).



Supplemental Figure S4. Representation of all tags in functional classes. The tags were manually allocated to the functional classes as used in the MENS database. Blue, red, yellow and green bars correspond respectively to tags specific to the common cluster, RHC cluster, LRB cluster and the cluster containing tags specific for inoculation with ORS571-V44. The number of tags belonging to specific classes is expressed as the percentage of the total number of tags within the respective cluster.



Supplemental Table S2. qPCR-primers for analysis of a subset of tags.

List of primers used to amplify a subset of tags by qRT-PCR for validation of the cDNA-AFLP.

gene	Sense Primer	Anti-sense Primer
WC002-BT11M22-259.3	TTGCCGCGCATAGACAGATG	TCTTTCAAACGCTTCACGTCAG
WC020BT23M14-343.0	CTGTGAGAGCCTGGTTAGACTG	CATCATAAGGCCACCGGATAGG
WC022BT24M13-265.0	GGGTTATGGAATATGTGCTGCTTG	GCTGCCACAACCACCTCTG
WC024BT24M42-288.2	TTCGGTTGTGTGCTCTGATCC	GGCAGCGATGAATAAGTTGTGG
WC029T31M41-395.6	GGAAGCCTAGCCACCAATTTAGC	TACAGTGATGGGACTCCTTACTTG
WC041BT42M22-281.9	ACCGCATTGTGATCCAACG	ACAAAGGCATTAGGATGAGGTC
WC043BT43M22-372.0	AATGTGGAAGAGGGCAGGATAG	CATACCCAACGCCAAGTAAGTC
WC048BT32M12-658.6	GAAGTGGCGGCGGTTATGG	AGACCAGCAAACCCTTCATCG
Srubiquitine1	GGGAAGCAGTTGGAGGATGG	AGACGCAGAACAAGGTGAAGG
SrLYR3	TTCCAGAACACAGACACCTACC	TGGGACAAGCACATCTAAGAGG
ELF1-α	ACTGTGCAGTAGTACTTGGTG	AAGCTAGGAGGTATTGACAAG
MtLYR3	AAGCATACCTCACCTTCAGAAC	CGGCGAGTTGAGATGGATTTG